Statins for major depressive disorder: A systematic review and meta-analysis of randomized controlled trials
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Background: The burden of depressive disorder is large and new treatment approaches are required. Repurposing widely available drugs such as statins may be a time- and cost-effective solution. Statins have anti-inflammatory and anti-oxidant properties which have been shown to be relevant to the pathophysiology of depression. This study assesses the efficacy, acceptability, tolerability, and safety of statins in major depressive disorder. Methods: Our study is an update and extension of a previous meta-analysis published in 2016 by Salagre et al. We performed a systematic review (PubMed/MEDLINE, Cochrane CENTRAL, ISI Web of Science, CINAHL, and ClinicalTrials.gov until the 1 st September 2020) and meta-analysis of randomized controlled trials using any statin against placebo or any other statin in the treatment of major depressive disorder. Our primary efficacy outcome measure was the mean value on any standardized scale for depressive symptoms at 8 weeks of treatment. We also calculated outcomes for efficacy, response, and remission at 2, 4, and 12 weeks, as well as acceptability (dropouts for any cause), tolerability (dropouts due to any adverse event), and safety (any adverse event) outcomes at the studies’ endpoints. Furthermore, we conducted an exploratory network meta-analysis for the primary efficacy outcome to identify potential differences between statins. Results: We retrieved five randomized controlled trials meeting our inclusion criteria: four used a statin in addition to an antidepressant and compared it to placebo plus antidepressant, and one compared two statins alone. and one comparing one statin with another. Statins compared to placebo in addition to antidepressants were efficacious at 8 weeks (N = 255, SMD = -0.48, 95% CI = -0.74 to -0. 22) and 12 weeks (N = 134, SMD = -0.47, 95% CI = -0.89 to -0.05, moderate certainty) with no difference for acceptability, tolerability, and safety (low certainty). An exploratory network meta-analysis suggested that the most lipophilic statins, especially simvastatin, could be more efficacious than less lipophilic or hydrophilic molecules. Conclusions: This systematic review suggests the efficacy, acceptability, tolerability, and safety of statins in addition to antidepressants in patients with major depressive disorder. Further clinical trials in different settings are required to test this result. Trial rgistration: PROSPERO registration: CRD42020170938.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 Main statins’ lipophilicity. Lipophilicity is measured as C log P octanol/water, i.e. higher values correspond to higher lipophilicity. Note that simvastatin, lovastatin, and atorvastatin [29] are considered lipophilic statins, whereas rosuvastatin [30] is a highly hydrophilic statin.](https://figures.cochat.ai/paper-figures/4c54525f28574e6aafb0808103678fc2/statins-for-major-depressive-disorder-a-systematic-review-and-meta-analysis-of-figure-1.jpg)


![Fig 4 Forest plot for acceptability (number of participants discontinuing treatment [dropouts] due to any cause) and for tolerability (number of participants discontinuing treatment [dropouts] due to adverse events).](https://figures.cochat.ai/paper-figures/752c5574411349ce9aebfe614aba939e/statins-for-major-depressive-disorder-a-systematic-review-and-meta-analysis-of-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A meta-analysis of RCTs found that the addition of a statin to an antidepressant had a moderate effect on reducing depressive scores compared to placebo at week 8 and 12 with no report of serious adverse events across all trials (170).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“In the Sequenced Treatment Alternatives to Relieve Depression (STARD) study, just under half of the patients responded to first-line pharmacological therapy and one-third still experienced significant symptoms after four treatment steps over one year of treatment [3].”
BackgroundInflammaging: a new immune–metabolic viewpoint for age-related diseases
Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., & Santoro, A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0059-4 · Cited by 3,586 · cited 1×
“BMI, stress, chronic ailments), a concept known as “inflammaging” [51].”
BackgroundCipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857 · cited 2×
“Statins are considered safe drugs: more common side-effect include muscle pain or weakness, elevation of liver transaminases, nasopharyngitis, pharyngo-laryngeal pain, epistaxis, headache, and gastrointestinal disturbances; whereas more serious yet rare adverse events include rhabdomyolysis, new-onset diabetes mellitu…”
BackgroundRaison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms
Jain, M. K., & Ridker, P. M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1901 · Cited by 915 · cited 1×
“These medications have significant anti-inflammatory and antioxidant effects that are rapid [10] and independent of their lipid-lowering properties [11].”
BackgroundNew insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796 · cited 1×
“Note that simvastatin, lovastatin, and atorvastatin [29] are considered lipophilic statins, whereas rosuvastatin [30] is a highly hydrophilic statin.”
BackgroundHow do antidepressants work? New perspectives for refining future treatment approaches
Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30015-9 · Cited by 616 · cited 1×
“Traditional antidepressants work in the main by modulating monoamine levels in the synaptic cleft [2] and are burdened by high rates of non-response.”
BackgroundSelf-citationEnache, D., Pariante, C. M., & Mondelli, V. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.06.015 · Cited by 615 · cited 1×
“Because there is evidence for central inflammation in depressed patients [49], it is possible that drugs able to modulate brain inflammatory mechanisms directly may be more therapeutically active.”
BackgroundKöhler‐Forsberg, O., N. Lydholm, C., Hjorthøj, C., Nordentoft, M., Mors, O., & Benros, M. E. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13016 · Cited by 432 · cited 2×
“This is in line with previously conducted meta-analyses [30, 32, 34, 35], which however included more heterogenous populations of depressed and non-depressed participants.”
ResultFurukawa, T. A., Cipriani, A., Atkinson, L. Z., Leucht, S., Ogawa, Y., Takeshima, N., Hayasaka, Y., Chaimani, A., & Salanti, G. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30307-8 · Cited by 219 · cited 1×
“In randomized placebocontrolled trials of antidepressants for the acute treatment of major depression, the placebo response rate ranges between 35% and 40% [4] versus 50% to 60% for antidepressants [5].”
BackgroundMcIntyre, R. S., Subramaniapillai, M., Lee, Y., Pan, Z., Carmona, N. E., Shekotikhina, M., Rosenblat, J. D., Brietzke, E., Soczynska, J. K., Cosgrove, V. E., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.0779 · Cited by 200
Molecular Mechanisms Underlying the Effects of Statins in the Central Nervous System
McFarland, A., Anoopkumar-Dukie, S., Arora, D., Grant, G., McDermott, C., Perkins, A., & Davey, A. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151120607 · Cited by 196 · cited 1×
“In view of their pleiotropy, well-established safety profile [26], and differential capacity to penetrate the brain parenchyma according to their lipophilicity [27] (Fig 1), the potential therapeutic use of statins has been extensively studied in depression [28].”
BackgroundRosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease
Luvai, A., Mbagaya, W., Hall, A. S., & Barth, J. H. (2012) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s4324 · Cited by 189 · cited 2×
“This is in line with previously conducted meta-analyses [30, 32, 34, 35], which however included more heterogenous populations of depressed and non-depressed participants.”
BackgroundResultTherapeutic Implications of Brain–Immune Interactions: Treatment in Translation
Miller, A. H., Haroon, E., & Felger, J. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.167 · Cited by 152 · cited 1×
“Previous authors have supported the importance of targeting a specific subset of depressed patients with concomitant increased inflammatory markers when using anti-inflammatories for antidepressant purpose [52]; in other words, applying a precision medicine approach to a psychopharmacological treatment.”
BackgroundShrivastava, S., Pucadyil, T. J., Paila, Y. D., Ganguly, S., & Chattopadhyay, A. (2010) · Biochemistry · doi:10.1021/bi100276b · Cited by 150 · cited 1×
“In vitro studies have shown that statin-mediated cholesterol depletion alters 5 hydroxytryptamine (5HT)1areceptor dynamics [12], while animal studies have reported that statins augment the serotonergic effects of some antidepressants [13] and increase hippocampal 5HT [14] and brain-derived neurotrophic factor [15–17]…”
BackgroundSalagre, E., Fernandes, B. S., Dodd, S., Brownstein, D. J., & Berk, M. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.04.047 · Cited by 117 · cited 2×
“This is in line with previously conducted meta-analyses [30, 32, 34, 35], which however included more heterogenous populations of depressed and non-depressed participants.”
ResultMacin, S. M., Perna, E. R., Farías, E. F., Franciosi, V. A., Cialzeta, J., Brizuela, M., Medina, F., Tajer, C. D., Doval, H. C., & Badaracco, J. R. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.07.041 · Cited by 103 · cited 1×
“These medications have significant anti-inflammatory and antioxidant effects that are rapid [10] and independent of their lipid-lowering properties [11].”
BackgroundStatins use and risk of depression: A systematic review and meta-analysis
Parsaik, A. K., Singh, B., M. Hassan, M., Singh, K., Mascarenhas, S. S., Williams, M. D., Lapid, M. I., Richardson, J. W., West, C. P., & Rummans, T. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.11.026 · Cited by 100 · cited 2×
“Compared to a previous meta-analysis on a sample of depressed participants only [33], we could add a more recent trial [42] that lead to a slightly lower effect size for our primary outcome of efficacy at 8 weeks, namely SMD = -0.”
ResultLudka, F. K., Zomkowski, A. D. E., Cunha, M. P., Dal-Cim, T., Zeni, A. L. B., Rodrigues, A. L. S., & Tasca, C. I. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.05.005 · Cited by 92
Atorvastatin prevents lipopolysaccharide-induced depressive-like behaviour in mice
Taniguti, E. H., Ferreira, Y. S., Stupp, I. J. V., Fraga-Junior, E. B., Doneda, D. L., Lopes, L., Rios-Santos, F., Lima, E., Buss, Z. S., Viola, G. G., et al. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.01.018 · Cited by 90
Ghanizadeh, A., & Hedayati, A. (2013) · Depression and Anxiety · doi:10.1002/da.22195 · Cited by 81 · cited 9×
“did not describe any procedure for allocation concealment, therefore it was at unclear risk of bias for allocation concealment and the linked items of blinding of participants, personnel, and outcome assessment [39].”
BackgroundMethodResultInfluentialThe impact of statins on psychological wellbeing: a systematic review and meta-analysis
O'Neil, A., Sanna, L., Redlich, C., Sanderson, K., Jacka, F., Williams, L. J., Pasco, J. A., & Berk, M. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-154 · Cited by 78 · cited 1×
“Despite earlier conflicting reports about the impact of statins on mood [31, 32], later metaanalyses of observational [33] and interventional [34] studies, including some investigating many other anti-inflammatories [35, 36], have indeed suggested that statins may have clinically meaningful antidepressant effects.”
ResultGougol, A., Zareh-Mohammadi, N., Raheb, S., Farokhnia, M., Salimi, S., Iranpour, N., Yekehtaz, H., & Akhondzadeh, S. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115578160 · Cited by 77 · cited 9×
“Efficacy at 2 weeks (2 trials [39, 41], 105 participants, SMD = -0.”
BackgroundMethodResultInfluentialStatin use and risk of depression: a Swedish national cohort study
Redlich, C., Berk, M., Williams, L. J., Sundquist, J., Sundquist, K., & Li, X. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0348-y · Cited by 76 · cited 1×
“Indeed, the previously mentioned Swedish cohort study did show a stepwise reduction in the odds of developing depression with increasing age for statin-users [45].”
BackgroundInvolvement of PI3K/Akt/GSK-3β and mTOR in the antidepressant-like effect of atorvastatin in mice
Ludka, F. K., Constantino, L. C., Dal-Cim, T. A., Binder, L. B., Zomkowski, A. D. E., Rodrigues, A. L. S., & Tasca, C. I. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.07.004 · Cited by 71 · cited 1×
“in aspartate receptor antagonism [24] and the PI3k/AKT/GSK-3b/mTor signalling pathway [25], which may also mediate the antidepressant of action of ketamine.”
BackgroundAbbasi, S. H., Mohammadinejad, P., Shahmansouri, N., Salehiomran, A., Beglar, A. A., Zeinoddini, A., Forghani, S., & Akhondzadeh, S. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.04.049 · Cited by 70 · cited 10×
“This analysis allowed the addition of 1 trial [43] that compared simvastatin to atorvastatin but did not have a placebo group.”
BackgroundMethodInfluentialBerk, M., Mohebbi, M., Dean, O. M., Cotton, S. M., Chanen, A. M., Dodd, S., Ratheesh, A., Amminger, G. P., Phelan, M., Weller, A., et al. (2020) · BMC Medicine · doi:10.1186/s12916-019-1475-6 · Cited by 68 · cited 11×
“The most recent article included a larger 15–25 years old sample of depressed patients followed-up for 12 weeks who were randomized to treatment as usual, defined as psychotherapy or antidepressant, plus either rosuvastatin, aspirin, or placebo; in this case, the statin group did slightly better than placebo, but the…”
BackgroundMethodResultInfluentialLim, S.-W., Shiue, Y., Liao, J.-C., Wee, H.-Y., Wang, C.-C., Chio, C., Chang, C.-H., Hu, C.-Y., & Kuo, J. (2016) · Neurocritical Care · doi:10.1007/s12028-016-0290-6 · Cited by 67
Haghighi, M., Khodakarami, S., Jahangard, L., Ahmadpanah, M., Bajoghli, H., Holsboer-Trachsler, E., & Brand, S. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.018 · Cited by 65 · cited 8×
“Two trials [40, 42] involved the measurement of blood lipids whose results, if revealed before the primary analyses on depressive scores, may have interfered with the investigators’ blinding.”
BackgroundMethodInfluentialSimvastatin prevents and ameliorates depressive behaviors via neuroinflammatory regulation in mice
Yu, X.-B., Zhang, H.-N., Dai, Y., Zhou, Z.-Y., Xu, R.-A., Hu, L.-F., Zhang, C.-H., Xu, H.-Q., An, Y.-Q., Tang, C.-R., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.11.086 · Cited by 62
Tsai, S. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.09.043 · Cited by 61
Do statins have an effect on depressive symptoms? A systematic review and meta-analysis
Yatham, M. S., Yatham, K. S., Ravindran, A. V., & Sullivan, F. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.002 · Cited by 61 · cited 1×
“Despite earlier conflicting reports about the impact of statins on mood [31, 32], later metaanalyses of observational [33] and interventional [34] studies, including some investigating many other anti-inflammatories [35, 36], have indeed suggested that statins may have clinically meaningful antidepressant effects.”
ResultThe effects of statins on mood: a review of the literature
While, A., & Keen, L. (2012) · European Journal of Cardiovascular Nursing · doi:10.1016/j.ejcnurse.2010.08.008 · Cited by 49 · cited 2×
“This is in line with previously conducted meta-analyses [30, 32, 34, 35], which however included more heterogenous populations of depressed and non-depressed participants.”
ResultLudka, F. K., Cunha, M. P., Dal-Cim, T. A., Binder, L. B., Constantino, L. C., Massari, C. M., Martins, W. C., Rodrigues, A. L. S., & Tasca, C. I. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0134-6 · Cited by 45
Shahsavarian, A., Javadi, S., Jahanabadi, S., Khoshnoodi, M., Shamsaee, J., Shafaroodi, H., Mehr, S. E., & Dehpour, A. R. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.004 · Cited by 41 · cited 1×
“The depressogenic effect of oxidative stress in the brain appears reduced both directly [22] and via peroxisome proliferator-activated receptor-γ activity and decreased nitrous oxide levels [23] by statins.”
BackgroundLudka, F. K., Dal-Cim, T. A., Binder, L. B., Constantino, L. C., Massari, C. M., & Tasca, C. I. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9882-6 · Cited by 41 · cited 1×
“The depressogenic effect of oxidative stress in the brain appears reduced both directly [22] and via peroxisome proliferator-activated receptor-γ activity and decreased nitrous oxide levels [23] by statins.”
BackgroundBacking into the future: pharmacological approaches to the management of resistant depression
Cowen, P. J. (2017) · Psychological Medicine · doi:10.1017/s003329171700068x · Cited by 40 · cited 1×
“Repurposing currently available medications to target alternative pathways implicated in depression may provide a solution to this problem [7, 8].”
BackgroundSelf-citationKim, S.-W., Kang, H.-J., Bae, K.-Y., Shin, I.-S., Hong, Y. J., Ahn, Y.-K., Jeong, M. H., Berk, M., Yoon, J.-S., & Kim, J.-M. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.07.003 · Cited by 37 · cited 1×
“Moreover, statins reduce depressive-like behaviors in rats by counteracting microglial and astrocyte activation as well as cytokine release in the central nervous system via inhibition of the nuclear factor-kB pathway and subsequent interleukin (IL)-1B, IL-6, and tumor necrosis factor-α secretion [18–20]; similarly, t…”
BackgroundAntidepressant-like effect of simvastatin in diabetic rats
ElBatsh, M. M. (2015) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2014-0560 · Cited by 34 · cited 1×
“In vitro studies have shown that statin-mediated cholesterol depletion alters 5 hydroxytryptamine (5HT)1areceptor dynamics [12], while animal studies have reported that statins augment the serotonergic effects of some antidepressants [13] and increase hippocampal 5HT [14] and brain-derived neurotrophic factor [15–17]…”
BackgroundDo Statins Have Antidepressant Effects?
Köhler-Forsberg, O., Gasse, C., Berk, M., & Østergaard, S. D. (2017) · CNS Drugs · doi:10.1007/s40263-017-0422-3 · Cited by 31
Simvastatin and Bezafibrate ameliorate Emotional disorder Induced by High fat diet in C57BL/6 mice
Wang, H., Zhou, J., Liu, Q. Z., Wang, L. L., & Shang, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-02576-5 · Cited by 29 · cited 1×
“in aspartate receptor antagonism [24] and the PI3k/AKT/GSK-3b/mTor signalling pathway [25], which may also mediate the antidepressant of action of ketamine.”
BackgroundOtte, C., Chae, W. R., Nowacki, J., Kaczmarczyk, M., Piber, D., Roepke, S., Märschenz, S., Lischewski, S., Schmidt, S. H., Ettrich, B., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040119 · Cited by 26 · cited 1×
“For example, a recently registered clinical trial will be using simvastatin in addition to escitalopram in a selected population of patients with depression and comorbid obesity [53].”
BackgroundDave, C. V., Winterstein, A. G., Park, H., Cook, R. L., & Hartzema, A. G. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.021 · Cited by 25
Three Paths to Drug Discovery in Psychiatry
Berk, M., & Nierenberg, A. A. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14070858 · Cited by 21 · cited 1×
“Repurposing currently available medications to target alternative pathways implicated in depression may provide a solution to this problem [7, 8].”
BackgroundHusain, M. I., Chaudhry, I. B., Khoso, A. B., Husain, M. O., Rahman, R. R., Hamirani, M. M., Hodsoll, J. P., Carvalho, A. F., Husain, N., & Young, A. H. (2019) · BJPsych Open · doi:10.1192/bjo.2018.84 · Cited by 18 · cited 1×
“Further clinical trials of statins in depressed patients should therefore consider the specific statins profile when selecting the molecule to be used: a currently running randomised controlled trial chose indeed to use simvastatin in addition to antidepressant [50].”
MethodAl-Asmari, A. K., Ullah, Z., Masoudi, A. A., & Ahmad, I. (2017) · Journal of Experimental Pharmacology · doi:10.2147/jep.s128696 · Cited by 15 · cited 1×
“In vitro studies have shown that statin-mediated cholesterol depletion alters 5 hydroxytryptamine (5HT)1areceptor dynamics [12], while animal studies have reported that statins augment the serotonergic effects of some antidepressants [13] and increase hippocampal 5HT [14] and brain-derived neurotrophic factor [15–17]…”
BackgroundGrand Challenge in Psychopharmacology: Setting Priorities to Shape a Bright Future
Ciccocioppo, R. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00015 · Cited by 12 · cited 1×
“Therefore, the need for new antidepressant drugs is compelling, but drug development in this therapeutic area is challenging and several pharmaceutical companies have disinvested from it [6].”
Background
Research works printed but not linked: 1
- C. National Clinical Guideline, National Institute for Health and Clinical Excellence: Guidance. Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease.
Cited by
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
“A meta-analysis of RCTs found that the addition of a statin to an antidepressant had a moderate effect on reducing depressive scores compared to placebo at week 8 and 12 with no report of serious adverse events across all trials (170).”
BackgroundYin, Y., Ju, T., Zeng, D., Duan, F., Zhu, Y., Liu, J., Li, Y., & Lu, W. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107322 · Cited by 177
Réus, G. Z., Manosso, L. M., Quevedo, J., & Carvalho, A. F. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105425 · Cited by 103
Du, Y., Dou, Y., Wang, M., Wang, Y., Yan, Y., Fan, H., Fan, N., Yang, X., & Ma, X. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1407529 · Cited by 64
Statins in Depression: An Evidence-Based Overview of Mechanisms and Clinical Studies
Giorgi, R. D., Pesci, N. R., Quinton, A. M. G., Crescenzo, F. D., Cowen, P. J., & Harmer, C. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.702617 · Cited by 56
Self-citation
Metadata
- Authors
- De Giorgi, R., De Crescenzo, F., Rizzo Pesci, N., Martens, M., Howard, W., Cowen, P. J., & Harmer, C. J.
- Affiliations
- Warneford Hospital (GB)
- Oxford Health NHS Foundation Trust (GB)
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-03-30
- Volume
- 16
- Issue
- 3
- Pages
- e0249409
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC8009386
- OpenAlex
- W3145353625
- Cited by
- 52
- References
- 50
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 6 · 2023: 14 · 2022: 12 · 2021: 5
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Wellcome Trust (102176/Z/13/Z; grant: 216452/Z/19/Z)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- statins, major depressive disorder, drug repurposing, antidepressant augmentation, simvastatin, lipophilicity, depressive symptoms, treatment response and remission, safety and tolerability, anti-inflammatory effects of statins, adverse events, dropout rates, placebo comparison
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.